Rooney Brian, Gouveia Goncalo Jorge, Isles Neville, Lawrence Lynda, Brodie Tara, Grahovac Zorana, Chamberlain Mark, Trotter Gavin
Toxicology Department, LGC Group, Queens Road, Teddington, Middlesex TW11 0LY, UK.
Kingston University, Penrhyn Road, Kingston Upon Thames, Surrey, KT1 2EE, UK.
J Anal Toxicol. 2017 Mar 1;41(2):140-145. doi: 10.1093/jat/bkw109.
This report details the blood concentration of drugs found in motorists suspected of driving under the influence of drugs from 2010 to 2012 in England and Wales. This study was carried out as new legislation has come into place, setting fixed blood concentration limits for drugs in motorists. These include a cannabis (Δ9-THC) blood concentration of 2 µg/L, amphetamine 250 µg/L, benzoylecgonine (BZE) 50 µg/L, cocaine 10 µg/L, 6-monoacetylmorphine 5 µg/L, morphine 80 µg/L, diazepam 550 µg/L and methadone 500 µg/L. Samples were screened for opiates, methadone, benzodiazepines, cannabinoids, cocaine, amphetamines and methamphetamine. Cannabinoids were the most prevalent drug group (29.7%) followed by benzodiazepines (22.7%), opiates (18.8%), cocaine (16.3%), amphetamine (7%) and methadone (5.6%). The analytical results are compared with the new per se limits to give a reference of drug concentrations prior to this legislation coming into effect. Our studies show that 64.9% of the cannabis samples, 59.1% of the cocaine samples and 94.6% of the BZE samples would be above the new per se limits set under Section 5a of the Road Traffic Act. In contrast, the medicinal drugs such as benzodiazepines and opiates (morphine) were predominantly detected at concentrations below the new per se limit. Given its medical applications, amphetamines appear to have been grouped with the medicinal type drugs, with our data showing that 25.2% of the amphetamine positive samples would exceed the new specified limit. These data show that samples containing medicinal and prescription drugs are likely to be detected below the new legal limits, while illicit drugs were typically found at concentrations above the new specified limits.
本报告详细介绍了2010年至2012年在英格兰和威尔士涉嫌药物影响驾驶的驾车者体内发现的药物血液浓度。这项研究是在新立法出台后进行的,该立法为驾车者设定了固定的药物血液浓度限值。这些限值包括大麻(Δ9-四氢大麻酚)血液浓度2微克/升、苯丙胺250微克/升、苯甲酰爱康宁(BZE)50微克/升、可卡因10微克/升、6-单乙酰吗啡5微克/升、吗啡80微克/升、地西泮550微克/升和美沙酮500微克/升。对样本进行了阿片类药物、美沙酮、苯二氮䓬类、大麻素、可卡因、苯丙胺和甲基苯丙胺的筛查。大麻素是最常见的药物类别(29.7%),其次是苯二氮䓬类(22.7%)、阿片类药物(18.8%)、可卡因(16.3%)、苯丙胺(7%)和美沙酮(5.6%)。将分析结果与新的本身限值进行比较,以提供该立法生效前药物浓度的参考。我们的研究表明,64.9%的大麻样本、59.1%的可卡因样本和94.6%的BZE样本将高于《道路交通法》第5a条规定的新的本身限值。相比之下,苯二氮䓬类和阿片类药物(吗啡)等药用药物主要在低于新的本身限值的浓度下被检测到。鉴于其医疗用途,苯丙胺似乎被归类为药用类型的药物,我们的数据显示,25.2%的苯丙胺阳性样本将超过新规定的限值。这些数据表明,含有药用和处方药的样本可能在新的法定限值以下被检测到,而非法药物通常在高于新规定限值的浓度下被发现。